An immunogenomic exome landscape of triple positive primary antiphospholipid patients

• Published in: Genes and immunity Vol. 25; no. 2; pp. 108 - 116
• Main Authors: Guffroy, A., Jacquel, L., Seeleuthner, Y., Paul, N., Poindron, V., Maurier, F., Delannoy, V., Voegeli, A. C., Zhang, P., Nespola, B., Molitor, A., Apithy, M. J., Soulas-Sprauel, P., Martin, T., Voll, R. E., Bahram, S., Gies, V., Casanova, J. L., Cobat, A., Boisson, B., Carapito, R., Korganow, A. S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2024; Nature Publishing Group
• Subjects: 631/208/248/144; 631/250/38; Antiphospholipid syndrome; Autoantibodies; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cardiolipin; Gene Expression; Genomics; Human Genetics; Immune system; Immunity; Immunological tolerance; Immunology; Phospholipids; Thromboembolism; Thrombosis
• ISSN: 1476-5470; 1466-4879; 1476-5470
• DOI: 10.1038/s41435-024-00255-w

Primary antiphospholipid syndrome is characterized by thrombosis and autoantibodies directed against phospholipids or associated proteins. The genetic etiology of PAPS remains unknown. We enrolled 21 patients with thromboembolic events associated to lupus anticoagulant, anticardiolipin and anti β2 glycoprotein1 autoantibodies. We performed whole exome sequencing and a systematic variant-based analysis in genes associated with thrombosis, in candidate genes previously associated with APS or inborn errors of immunity. Data were compared to public databases and to a control cohort of 873 non-autoimmune patients. Variants were identified following a state-of-the-art pipeline. Enrichment analysis was performed by comparing with the control cohort. We found an absence of significant HLA bias and genetic heterogeneity in these patients, including when testing combinations of rare variants in genes encoding for proteins involved in thrombosis and of variants in genes linked with inborn errors of immunity. These results provide evidence of genetic heterogeneity in PAPS, even in a homogenous series of triple positive patients. At the individual scale, a combination of variants may participate to the breakdown of B cell tolerance and to the vessel damage.